stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) P/S ratio
As of 5 November 2026, IDEAYA Biosciences, Inc. (IDYA) trades at a P/S ratio of 86.7×. Over the past ten years it has ranged from 0.0× (June 2021) to 144× (July 2024); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 13.3× | (85.23%) |
| FY2024 | 89.8× | 3.62% |
| FY2023 | 86.6× | 512.54% |
| FY2022 | 14.1× | (52.58%) |
| FY2021 | 29.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 108× | 638.70% |
| Jun 2026 | 14.7× | 13.65% |
| Mar 2026 | 12.9× | (2.76%) |
| Dec 2025 | 13.3× | 22.95% |
| 15 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.6× |
| BEAM Beam Therapeutics Inc. compare | 18.6× |
| IDYA IDEAYA Biosciences, Inc. | 86.7× |
| VRDN Viridian Therapeutics, Inc. compare | 118× |
| DNLI Denali Therapeutics Inc. compare | 165× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement